{"id":"W2167290534","doi":"10.1158/1078-0432.ccr-06-1432","title":"Phase I Trial of Sorafenib in Combination with IFN α-2a in Patients with Unresectable and/or Metastatic Renal Cell Carcinoma or Malignant Melanoma","year":2007,"lang":"en","type":"article","venue":"Clinical Cancer Research","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":140,"is_retracted":false,"has_abstract":true,"ca_institutions":"Immunovaccine (Canada)","funders":"","keywords":"Sorafenib; Medicine; Renal cell carcinoma; Melanoma; Internal medicine; Response Evaluation Criteria in Solid Tumors; Oncology; Pharmacokinetics; Adverse effect; Cohort; Progressive disease; Gastroenterology; Combination therapy; Chemotherapy; Hepatocellular carcinoma; Cancer research","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001190205,0.001670723,0.002152516,0.0003324556,0.0004408321,0.0009096434,0.0008519551,0.0009835487,0.002747457],"category_scores_gemma":[0.0008820317,0.0006337804,0.001055064,0.0003174598,0.0009909585,0.0005916779,0.0003216695,0.002918493,0.0007082067],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.000916037,"about_ca_system_score_gemma":0.001770323,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0008903378,"about_ca_topic_score_gemma":0.002181158,"domain_scores_codex":[0.9996113,0.0002010529,0.00001994728,0.00005662321,0.000030249,0.00008082184],"domain_scores_gemma":[0.9992554,0.0001097455,0.0001379014,0.00005304479,0.00003704561,0.0004068592],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.8278846,0.05788301,0.008335155,0.0006655318,0.001173326,0.0004440367,0.0002805911,0.00287037,0.03213139,0.0002266225,0.003296632,0.0648088],"study_design_scores_gemma":[0.7144458,0.2724794,0.007435658,0.00002845709,0.0002485633,0.0002125695,0.00003841514,0.001241571,0.002218473,0.0001140625,0.001518458,0.00001864678],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9945651,0.00134218,0.0003573626,0.0005036988,0.0001661315,0.001553543,0.0004084963,0.00006603607,0.001037452],"genre_scores_gemma":[0.9930958,0.0009516753,0.0008825117,0.0006095812,0.0002346631,0.001671152,0.001101854,0.00001561131,0.001437142],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.002747457,"threshold_uncertainty_score":0.009191096,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1713359032877744,"score_gpt":0.4647006839402991,"score_spread":0.2933647806525246,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}